Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)

Inclusion Criteria: * Completion of study SNT-II-001 * Body weight ≥ 25 kg * Glucocorticosteroids and ACE-inhibitors are allowed, if on stable dosage within 2 months prior to inclusion * Eligibility to participate in the present extension study as confirmed by the investigator Exclusion Criteria: * Safety or tolerability issues arising during the course of SNT-II-001 which in the opinion of the investigator preclude further treatment with idebenone * Clinically significant abnormalities of haematology or biochemistry * Abuse of drugs or alcohol * Use of coenzyme Q10 or idebenone within 30 days prior to inclusion * Intake of any investigational drug within 30 days prior to inclusion * Symptomatic heart failure * Previous history of ventricular arrhythmias (other than isolated ventricular extrasystole); ventricular arrhythmias presented at baseline * Known individual hypersensitivity to idebenone or to any of the excipients